Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences

Texto completo
Autor(es):
Montico, Fabio [1] ; Kido, Larissa Akemi [1] ; Martin, Rebeca San [2] ; Rowley, David R. [2] ; Cagnon, Valeria H. A. [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Dept Struct & Funct Biol, Inst Biol, UNICAMP, Campinas, SP - Brazil
[2] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 - USA
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: PROSTATE; v. 75, n. 14, p. 1643-1661, OCT 1 2015.
Citações Web of Science: 8
Resumo

BACKGROUNDProstate cancer is associated to a reactive stroma microenvironment characterized by angiogenic processes that are favorable for tumor progression. Senescence has been identified as a predisposing factor for prostate malignancies. In turn, the relationships between aging, reactive stroma, and the mechanisms that induce this phenotype are largely unknown. Thus, we investigated the occurrence of reactive stroma in the mouse prostate during advanced age as well as the effects of antiangiogenic and androgen ablation therapies on reactive stroma recruitment. METHODSMale mice (52-week-old FVB) were treated with two classes of angiogenesis inhibitors: direct (TNP-470; 15mg/kg; s.c.) and/or indirect (SU5416; 6mg/kg; i.p.). Androgen ablation was carried out by finasteride administration (20mg/kg; s.c.), alone or in association to both inhibitors. The Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model was used as a paradigm of cancer-associated reactive stroma. The dorsolateral prostate was collected for -actin (SMA), vimentin (VIM), and transforming growth factor-beta (TGF-) immunohistochemical and Western blotting analyses as well as for CD34/SMA and CD34/VIM colocalization. RESULTSSenescence was associated with increased SMA, VIM, and TGF- expression as well as with the recruitment of CD34/SMA and CD34/VIM dual-positive fibroblasts. These observations were similar to those verified in TRAMP mice. Antiangiogenic treatment promoted the recovery of senescence-associated stromal changes. Hormonal ablation, despite having led to impaired CD34/SMA and CD34/VIM dual-positive cell recruitment, did not result in decreased stimulus to reactive stroma development, due to enhanced TGF- expression in relation to the aged controls. CONCLUSIONSReactive stroma develops in the prostate of non-transgenic mice as a result of aging. The periacinar microvasculature is a candidate source for the recruitment of reactive stroma-associated cells, which may be derived either from perivascular-resident mesenchymal stem cells (MSCs) or from an endothelial-to-mesenchymal transition (EndMT) process. Thus, antiangiogenic therapy is a promising approach for preventing age-associated prostate malignancies by means of its negative interference in the development of reactive stroma phenotype from the vascular wall. Prostate 75:1643-1661, 2015. (c) 2015 Wiley Periodicals, Inc. (AU)

Processo FAPESP: 10/51112-5 - Terapias antigênicas e caracterização das células-tronco prostáticas (CTP) normais e cancerosas no modelo de camundongo transgênico para adenocarcinoma de próstata (TRAMP)
Beneficiário:Valéria Helena Alves Cagnon Quitete
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 11/01968-3 - Estroma reativo e próstata: senescência e inibição da angiogênese x lesões glandulares no modelo TRAMP
Beneficiário:Fabio Montico
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 12/03010-4 - Caracaterização molecular da próstata frente às terapias hormonais e antiangiogênicas em camundongos senis (FVB) e no modelo transgênicos (Tramp) para adenocarcinoma de próstata
Beneficiário:Valéria Helena Alves Cagnon Quitete
Linha de fomento: Auxílio à Pesquisa - Regular